Aminex Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of a novel small molecule combination therapy for the treatment of a broad range of cancer indications. Aminex has advanced AMXT 1501 + DFMO through target discovery, patenting, pre-clinical research and now into clinical development for the potential benefit of cancer patients.